Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome

Wilbert Bor; Diana Gorog

doi:10.3390/jcm9072020

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome

Wilbert Bor, Diana Gorog

Research output: Contribution to journal › Article › peer-review

16 Downloads (Pure)

Abstract

Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.

Original language	English
Number of pages	14
Journal	Journal of Clinical Medicine (JCM)
Volume	9
Issue number	7
Early online date	27 Jun 2020
DOIs	https://doi.org/10.3390/jcm9072020
Publication status	Published - 1 Jul 2020

Access to Document

10.3390/jcm9072020Licence: CC BY

jcm-09-02020
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Final published version, 230 KBLicence: CC BY

Cite this

@article{3e5a848bd4e44ed3b1a7df752fc146f8,

title = "Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome",

abstract = "Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.",

author = "Wilbert Bor and Diana Gorog",

note = "{\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",

year = "2020",

month = jul,

day = "1",

doi = "10.3390/jcm9072020",

language = "English",

volume = "9",

journal = "Journal of Clinical Medicine (JCM)",

issn = "2077-0383",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "7",

}

TY - JOUR

T1 - Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome

AU - Bor, Wilbert

AU - Gorog, Diana

N1 - © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.

AB - Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.

U2 - 10.3390/jcm9072020

DO - 10.3390/jcm9072020

M3 - Article

SN - 2077-0383

VL - 9

JO - Journal of Clinical Medicine (JCM)

JF - Journal of Clinical Medicine (JCM)

IS - 7

ER -

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome

Abstract

Access to Document

Fingerprint

Cite this